Oncotrap Inc.
Chapel Hill, NC Doing business as Oncotrap Inc.
- UEI
- KX22VNNMBYZ3
- CAGE
- 7PVZ5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 1168 Legend Oaks Dr, Chapel Hill, NC 27517, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| An aptamer-directed IGG1-FC drug conjugate (afdc) for treating pancreatic cancer - abstract pancreatic ductal… | National Cancer Institute | $355,257 | |
| Development of a dual chemokine CCL2/CCL5 neutralizing single-domainantibody for treating non-alcoholic… | National Institute of Diabetes and Digestive and Kidney Diseases | $331,729 | |
| Mrna delivery of a panel of single-domain antibodies for combinatorial deciphering of therapeutic targets for covid-19… | National Institute of Allergy and Infectious Diseases | $264,863 |
About Oncotrap Inc.
Oncotrap Inc. is a corporate entity registered to receive federal awards from the U.S. government. Based on the awarded grants, Oncotrap specializes in developing innovative therapeutic biologics and drug delivery platforms for the treatment of cancer, liver diseases, and infectious diseases.
Oncotrap has received several federal grants from the National Institutes of Health (NIH) to pursue research projects in these areas. A $400,000 grant from the National Cancer Institute supported the development of an aptamer-directed IgG1-Fc drug conjugate platform for treating pancreatic ductal adenocarcinoma. Another $361,400 grant from the National Institute of Diabetes and Digestive and Kidney Diseases funded research on a bispecific single-domain antibody targeting chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis. Additionally, a $299,128 grant from the National Institute of Allergy and Infectious Diseases supported the creation of an mRNA-delivered single-domain antibody library for combinatorial deciphering of therapeutic targets for COVID-19 related cytokine release syndrome. These grants demonstrate Oncotrap's expertise in antibody and aptamer-based therapeutics, drug conjugates, and mRNA delivery platforms for various disease areas, including cancer, liver diseases, and infectious diseases.
Quick answers
What is Oncotrap Inc.'s UEI?
Oncotrap Inc.'s Unique Entity ID (UEI) in SAM.gov is KX22VNNMBYZ3.
What is Oncotrap Inc.'s CAGE code?
Oncotrap Inc.'s CAGE code is 7PVZ5.
What is Oncotrap Inc.'s primary NAICS code?
Oncotrap Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Oncotrap Inc. located?
Oncotrap Inc.'s physical address in SAM.gov is 1168 Legend Oaks Dr, Chapel Hill, NC 27517, USA.
Is Oncotrap Inc. registered in SAM.gov?
Yes. Oncotrap Inc.'s SAM.gov registration is active through February 28, 2027.
What is Oncotrap Inc.'s most recent federal award?
Oncotrap Inc.'s most recent federal grant award is An aptamer-directed IGG1-FC drug conjugate (afdc) for treating pancreatic cancer - abstract pancreatic ductal… (R43CA281460), from National Cancer Institute, on September 22, 2023.
On GovTribe
See Oncotrap Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors